EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 62014CA0271
Joined Cases C-271/14 and C-273/14: Judgment of the Court (Eighth Chamber) of 16 April 2015 (request for a preliminary ruling from the Conseil d’État (France)) — LFB Biomédicaments SA, Association des déficitaires en Alpha 1 Antitrypsine (Association ADAAT Alpha 1-France) (C-271/14), Pierre Fabre Médicament SA (C-273/14) v Ministre des Finances et des Comptes publics, Ministre des Affaires sociales et de la Santé (Reference for a preliminary ruling — Medicinal products for human use — Directive 89/105/EEC — Article 6(3) and (5) — Removal of medicinal products from a list of pharmaceutical proprietary products covered in addition to fixed payments in respect of hospital treatment — Obligation to state reasons)
Joined Cases C-271/14 and C-273/14: Judgment of the Court (Eighth Chamber) of 16 April 2015 (request for a preliminary ruling from the Conseil d’État (France)) — LFB Biomédicaments SA, Association des déficitaires en Alpha 1 Antitrypsine (Association ADAAT Alpha 1-France) (C-271/14), Pierre Fabre Médicament SA (C-273/14) v Ministre des Finances et des Comptes publics, Ministre des Affaires sociales et de la Santé (Reference for a preliminary ruling — Medicinal products for human use — Directive 89/105/EEC — Article 6(3) and (5) — Removal of medicinal products from a list of pharmaceutical proprietary products covered in addition to fixed payments in respect of hospital treatment — Obligation to state reasons)
Joined Cases C-271/14 and C-273/14: Judgment of the Court (Eighth Chamber) of 16 April 2015 (request for a preliminary ruling from the Conseil d’État (France)) — LFB Biomédicaments SA, Association des déficitaires en Alpha 1 Antitrypsine (Association ADAAT Alpha 1-France) (C-271/14), Pierre Fabre Médicament SA (C-273/14) v Ministre des Finances et des Comptes publics, Ministre des Affaires sociales et de la Santé (Reference for a preliminary ruling — Medicinal products for human use — Directive 89/105/EEC — Article 6(3) and (5) — Removal of medicinal products from a list of pharmaceutical proprietary products covered in addition to fixed payments in respect of hospital treatment — Obligation to state reasons)
OJ C 198, 15.6.2015, p. 14–14
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
15.6.2015 |
EN |
Official Journal of the European Union |
C 198/14 |
Judgment of the Court (Eighth Chamber) of 16 April 2015 (request for a preliminary ruling from the Conseil d’État (France)) — LFB Biomédicaments SA, Association des déficitaires en Alpha 1 Antitrypsine (Association ADAAT Alpha 1-France) (C-271/14), Pierre Fabre Médicament SA (C-273/14) v Ministre des Finances et des Comptes publics, Ministre des Affaires sociales et de la Santé
(Joined Cases C-271/14 and C-273/14) (1)
((Reference for a preliminary ruling - Medicinal products for human use - Directive 89/105/EEC - Article 6(3) and (5) - Removal of medicinal products from a list of pharmaceutical proprietary products covered in addition to fixed payments in respect of hospital treatment - Obligation to state reasons))
(2015/C 198/18)
Language of the case: French
Referring court
Conseil d’État
Parties to the main proceedings
Applicants: LFB Biomédicaments SA, Association des déficitaires en Alpha 1 Antitrypsine (Association ADAAT Alpha 1-France) (C-271/14), Pierre Fabre Médicament SA (C-273/14)
Defendants: Ministre des Finances et des Comptes publics, Ministre des Affaires sociales et de la Santé
Operative part of the judgment
Article 6 of Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems must be interpreted as meaning that the obligation to state reasons provided for in Article 6(3) and (5) is applicable to a decision which restricts the conditions of reimbursement or reduces the level of coverage of a medicinal product by excluding it from the list of proprietary medicinal products covered by compulsory health insurance schemes in addition to services relating to hospital treatment covered by fixed payments in respect of periods of hospitalisation and hospital care.